The Food and Drug Administration (FDA) has approved Syfovre (Pegcetacoplan injection for intravitreale use) for the treatment of geographical atrophy (GA) secondary to age-related macular degeneration (AMD).
Admission was based on data from the phase -3 derby (clinicalaltrials.gov Identifier: NCT03525600) and OAKS (Clinicaltrials.gov Identifier: NCT03525613) Studies in which the effectiveness and safety of intravitreal pegcetacoplan in 1258 patients with GA patients with GA -Patients with AMD patients were examined for Amdreal. The patients were assigned to 2: 2: 1: 1 to either receive 15 mg/0.1 ml once a month, Pegcetacoplan 15 mg/0.1 ml every other month, every other month one month or apparently. The primary endpoint for both studies was the change in the total area of GA lesions from the starting value, measured by Fundus Autofluorescence after 12 months.
In derby, treatment with pegcetacoplan and in all two months reduced the rate of GA lesion growth by 18.1% or 17.4%, from initial value to month 24. In the case of oak, treatment with pegcetacoplan reduced the rate of the GA Lesion growth by 21.9% and 18.1%.
“So far there have been no approved therapies that have relentlessly rejected people with GA as their vision,” said Eleonora Lad, PhD, Senior Investigator for the OAKS study, director of clinical research in ophthalmology, Associate Professor of Ophthalmology, Duke University Medical Center. “With Syfovre we finally have a safe and effective GA treatment for this devastating disease with increasing effects over time.”
One of the most common side effects reported with pegcetacoplan were eye problems, neovascular age -related macular degeneration, vitreous swimmers and conjunctive bleeding. Treatment is contraindicated for use in patients with eye or periocular infections and patients with active intraocular inflammation.
Syfovre is delivered in a single-dose bottle with 150 mg/ml pegcetacoplan. It will probably be available at the beginning of March by special distributors and special pharmacies.
Apellis also offers patient support and resources via the Apellisissist program.
References
- FDA approved Syfovre (Pegcetacoplan injection) As the first and only treatment for geographical atrophy (GA), a main cause of blindness. Press release. Apellis Pharmaceuticals, Inc. Access on February 21, 2023.
- Syfovre. Package insert. Apellis Pharmaceuticals, Inc.; 2023. Access on February 21, 2023. Https://pi.apellis.com/files/pi_syfovre.pdf.
This article originally appeared on MPR